# Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

> **NCT07520006** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Nurix Therapeutics, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- B-cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** NX-5948
- **DRUG:** venetoclax
- **DRUG:** rituximab
- **DRUG:** obinutuzumab

## Key facts

- **NCT ID:** NCT07520006
- **Lead sponsor:** Nurix Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2033-05
- **Final completion:** 2033-05
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07520006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07520006, "Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07520006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*